

06-01-06

Cofc



Please type a plus sign (+) inside this box → +

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

		Issued Patent No.	7,034,058	101634641
		Issued Date	April 25, 2006	
		Application Number	10/634,641	
		Filing Date	August 4, 2003	
		First Named Inventor	TAKAHATA, KYOYA	
		Group Art Unit	1614	
		Examiner Name	Delacroix Muirhei, Cybille	
Total Number of Pages in This Submission	4	Attorney Docket Number	ORIN-004	

**ENCLOSURES (check all that apply)**

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> <input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <b>Petition for Certification of Correction (1 pg.)</b>
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<b>Certificate of Correction (1 pg.)</b>
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	<b>Copy of Column 12 with Change (1 pg.)</b>
<input type="checkbox"/> Certified Copy of Priority Documents	<input type="checkbox"/> CD, Number of CD(s)	<b>Postcard</b>
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Signing Attorney/Agent (Reg. No.)	CAROL L. FRANCIS, 36,513 BOZICEVIC, FIELD & FRANCIS, LLP	
Signature		
Date	May 30, 2006	

**Certificate****JUN 06 2006****of Correction****EXPRESS MAIL LABEL NO. EV 687 637 510 US**

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

JUN 06 2006



EXPRESS MAIL LABEL NO. EV 687 637 510 US

<b>PETITION FOR CERTIFICATE OF CORRECTION</b>  Address to: Mail Stop DAC Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	ORIN-004
	First Named Inventor	TAKAHATA, KYOYA
	Patent Number	7,034,058
	Issue Date	April 25, 2006
	Application Number	10/634,641
	Filing Date	August 4, 2003
	Title:	<i>"ANTI-TUMOR PHARMACEUTICAL COMPOSITION COMPRISING N-VANILLYL FATTY ACID AMIDE"</i>


Sir:

Transmitted herewith for filing is a Certificate of Correction for the above-identified patent. In *column 12, line 9, please replace "(C016)" with -- (C16) --*. Enclosed is a copy of column 12 showing the change.

It is believed that no fee is due since the error was made by the Patent and Trademark Office. However, the Commissioner is hereby authorized to charge any fees under 37 C.F.R. § 1.20, which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815 order number ORIN-004.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

By: \_\_\_\_\_

  
Carol L. Francis  
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP  
1900 University Avenue, Suite 200  
East Palo Alto, California 94303  
Telephone: (650) 327-3400  
Fax: (650) 327-3231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.  
(Also form PTO-1050)

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 7,034,058

DATED : April 25, 2006

INVENTOR(S) : TAKAHATA, KYOYA, et al.

It is certified that error appears in the above-identified patent and that said Letters Patent  
is hereby corrected as shown below:

In Column 12, line 9, please delete "(C016)" and replace with -- (C16) --

MAILING ADDRESS OF SENDER:

BOZICEVIC, FIELD & FRANCIS LLP  
1900 University Avenue, Suite 200  
East Palo Alto, California 94303

PATENT NO. 7,034,058

No. of additional copies



Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comment on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

11JN 06 2006

## 11

## EFFECT OF THE INVENTION


The present invention provides a pharmaceutical composition having an anti-tumor effect, in particular, an anti-melanoma effect and an anti-leukemia cell effect. In particular, the present invention provides an anti-tumor pharmaceutical composition having little side-effect to normal cells like capsaicin; having a high anti-tumor effect, in particular, an anti-melanoma effect and an anti-leukemia cell effect; and not having hotness, stimulus and proinflammatory effect.

It has been reported that capsaicin, which is a compound related to the N-vanillyl fatty acid amide of the present invention, has an anti-tumor effect both in vitro and in vivo, and both of the data obtained in vitro or in vivo are correlative (Eur J. Cancer. 1996 October; 32A(11): 1995-2003). Both of the N-vanillyl fatty acid amide of the present invention and capsaicin induce an apoptosis to suppress the growth of tumor cells, and have in common the vanillyl amine structure binding to a vaniloid receptor known as an in vivo receptor (A. Szallasi et.al., Life Sci., 47, 1399-1408 (1990)).

Taking this point into consideration, although the present specification does not state the in vivo data, it is apparent to those skilled in the art that the pharmaceutical composition will be effective in vivo.

The invention claimed is:

1. A method for the treatment of melanoma or leukemia comprising administering to a patient in need thereof an effective amount of a N-vanillyl fatty acid amide of formula (1):



(1)

35

(2)

30

(3)

35

## 12

wherein —CO—R group represents a saturated or unsaturated fatty acid residue containing from 14 to 32 carbon atoms.

5 2. The method of claim 1, wherein the —CO—R group is a member selected from the group consisting of saturated fatty acid residues containing from 14 to 32 carbon atoms.

10 3. The method of claim 2, wherein the —CO—R group is a member selected from the group consisting of myristic acid residue (C14), palmitic acid residue (C016) and stearic acid residue (C18). (C16)

15 4. The method of claim 1, wherein the —CO—R group is a member selected from the group consisting of unsaturated fatty acid residues containing from 14 to 32 carbon atoms.

20 5. The method of claim 4, wherein the —CO—R group is a member selected from the group consisting of unsaturated fatty acid residues having from 1 to 3 double bonds and containing 18 carbon atoms and unsaturated (any acid residues having 4 or 5 double bonds and containing 20 carbon atoms.

25 6. The method of claim 5, wherein the —CO—R group is a member selected from the group consisting of oleic acid residue (C18:1), ricinoleic acid residue (C18:1), linoleic acid residue (C18:2), linolens acid residue (C18:3) and eleostearis acid residue (C18:3).

30 7. The method of claim 5, wherein the —CO—R group is a member selected from the group consisting of arachidonic acid residue (C20:4) and eicosapentaeoic acid residue (C20:5).

35 8. The method of claim 4, wherein the —CO—R group is a member selected from the group consisting of unsaturated fatty acid residues having four or more double bonds and containing 22, 24, 26, 28 or 32 carbon atoms.

9. The method of claim 8, wherein the —CO—R group is 4,7,10,13,16,19-docosahexaenoic acid residue (C22:6).

\* \* \* \* \*